![PCR new 2014 masthead 1 1](https://prodcraftsa01.blob.core.windows.net/assets/products/primary-care-reports/_contentImage/PCR_new_2014_masthead_1__1.png)
Primary Care Reports – October 1, 2004
October 1, 2004
View Archives Issues
-
Pharmacology Watch: Linking COX-2 Inhibitors and Cardiovascular Event Risk
A new, and as of yet unpublished study, has raised increased concern about the relationship between rofecoxib (Vioxx), Mercks blockbuster COX-2 inhibitor, and cardiovascular events. -
Clinical Briefs in Primary Care Supplement